Rizatriptan benzoate 5 mg Disintegrating Oral Tablet
RxNorm 312839

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 312839 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: rizatriptan benzoate 5 mg Disintegrating Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Rizatriptan 5 mg Disintegrating Oral Tablet
Primary clinical definition
AUI:6352689
FN
Product containing precisely rizatriptan (as rizatriptan benzoate) 5 mg/1 each conventional release orodispersible tablet (clinical drug)
AUI:11440652
PT
Rizatriptan (as rizatriptan benzoate) 5 mg orodispersible tablet
AUI:11441153
SY
Rizatriptan 5 mg (as rizatriptan benzoate 7.265 mg) Disintegrating Oral Tablet
AUI:6356455
PSN
Rizatriptan benzoate 5 mg Disintegrating Oral Tablet
AUI:6360807

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
Rizatriptan 5 mg Disintegrating Oral Tablet
(Atom ID: 6352689)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
rizatriptan 5 MG Disintegrating Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
312839
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6352689
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
312839
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{330766} 237082
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{330766} 88014
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
5 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{330766} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans

FNPrescribable

Full form of descriptor (FN):
Product containing precisely rizatriptan (as rizatriptan benzoate) 5 mg/1 each conventional release orodispersible tablet (clinical drug)
(Atom ID: 11440652)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely rizatriptan (as rizatriptan benzoate) 5 milligram/1 each conventional release orodispersible tablet (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
312839
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11440652
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
766071005
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.

PTPrescribable

Designated preferred name (PT):
Rizatriptan (as rizatriptan benzoate) 5 mg orodispersible tablet
(Atom ID: 11441153)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Rizatriptan (as rizatriptan benzoate) 5 mg orodispersible tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
312839
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11441153
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
766071005
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.

SYPrescribable

Synonym (SY):
Rizatriptan 5 mg (as rizatriptan benzoate 7.265 mg) Disintegrating Oral Tablet
(Atom ID: 6356455)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
rizatriptan 5 MG (as rizatriptan benzoate 7.265 MG) Disintegrating Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
312839
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6356455
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
312839
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

PSNPrescribable

Prescribable Name (PSN):
Rizatriptan benzoate 5 mg Disintegrating Oral Tablet
(Atom ID: 6360807)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
rizatriptan benzoate 5 MG Disintegrating Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
312839
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6360807
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
312839
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Rizatriptan


Rizatriptan is used to treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Rizatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Rizatriptan does not prevent migraine attacks or reduce the number of headaches you have.
[Learn More]


* Please review the disclaimer below.